Skip to Main Content
Skip Nav Destination

Clofazimine Reduces Side Effects from Dual Immune Checkpoint Blockade

April 1, 2024

Major Finding: Clofazimine boosts dual anti–PD-1 and –CTLA-4 therapy efficacy and reduces immune-related adverse events.

Concept: Clofazimine-induced chromatin opening at E2F1 target loci led to stem memory T-cell differentiation.

Impact: Adjuvant clofazimine may enable patients to continue treatment with dual immune checkpoint blockade.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal